World Breast Biopsy Market - Opportunities and Forecasts, 2014 - 2022

  • ID: 3772952
  • Report
  • Region: Global
  • 170 pages
  • Allied Analytics LLP
1 of 4
Breast biopsy is a preliminary test that detects the area of an abnormal tissue growth or diagnoses the presence of cancerous cells. Defects or abnormalities are detected in the cell with the help of devices, such as vacuum-assisted biopsy, core needle biopsy, and fine needle biopsy. Moreover, assist the surgeons or radiologist performing the biopsy and using specialized imaging equipment, such as ultrasound, mammography-guided stereotactic biopsy that employs x-ray, and others.

The breast biopsy market was valued at $976.7 million in 2016, and is projected to reach at $1,420 million by 2023, growing at a CAGR of 5.3% from 2017 to 2023. This is attributed to the growth in incidence of breast cancer, increase in awareness regarding breast cancer screening programs, rise in demand for minimally invasive surgeries for breast biopsy, and new reimbursement guidelines for biopsy procedures in the U.S.. However, various regulatory issues and risks of infection in breast biopsy procedures hamper the market growth. The developing countries are expected to offer abundant growth opportunities to the breast biopsy market.

The global breast biopsy market is segmented on the basis of product, image-guided technology, end user, and geography. On the basis of product, it is classified into vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). Based on image guided technology, it is divided into MRI-guided biopsy, ultrasound guided biopsy, mammography guided stereotactic biopsy, CT-guided biopsy, and others. On the basis of end user, it is bifurcated into diagnostic centers and hospitals. Geographically, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.

KEY BENEFITS

This report provides an extensive analysis of the current & emerging market trends and dynamics in the global breast biopsy market.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
This report entails the detailed quantitative analysis of the current trends and future estimations to identify the prevailing opportunities.
Comprehensive analysis of factors that drive and restrict the market growth is provided.
Region- and country-wise market conditions are analyzed in the report.

Breast Biopsy Market Key Segments:

By Product

Vacuum Assisted Biopsy (VAB)
Core Needle Biopsy (CNB)
Fine Needle Aspiration Biopsy (FNAB)

By Image Guided Technology

MRI-Guided Biopsy
Ultrasound Guided Biopsy
Mammography Guided Stereotactic Biopsy
CT-Guided Biopsy
Others

By End User

Diagnostic Centers
Hospitals

By Geography

North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
Spain
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Singapore
Philippines
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Israel
Saudi Arabia
South Africa
Rest of LAMEA

KEY PLAYERS

Hologic Inc.
Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.)
C. R. Bard, Inc.
Becton and Dickinson Company
Argon Medical Devices
Cook Medical Incorporated
Encapsule medical Devices LLC.
Ethicon Endo Surgery (Johnson & Johnson)
Intact Medical Corporation
Galini SRL

OTHER PLAYERS

Zenalux Biomedical, Inc.
F. Hoffmann-La Roche Ltd.
OncoCyte Corporation
Laboratory Corporation of America Holdings (Labcorp)
Scion Medical Technologies
Planmed Oy
Aurora Imaging Technology Inc.
Carestream Health
Cardinal Health
PerkinElmer
READ MORE
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1 INTRODUCTION
1.1. KEY BENEFITS
1.2. KEY MARKET SEGMENTS
1.3. KEY PLAYERS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top winning strategies
3.2.2. Top investment pockets
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK AND REIMBURSEMENT SCENARIO
3.5. TOP PLAYER POSITIONING, 2016
3.6. MARKET DYNAMICS
3.6.1. Drivers
3.6.1.1. Rise in incidence rate of breast cancer
3.6.1.2. Advent of novel and minimal invasive biopsy procedures
3.6.1.3. Increase in number of breast cancer screening programs
3.6.1.4. Technological advancements in breast imaging equipment
3.6.2. Restraints
3.6.2.1. Uncertain regulatory issues
3.6.2.2. Infectious risk associated with breast biopsy procedures
3.6.2.3. High cost and unclear reimbursement policies
3.6.3. Opportunities
3.6.3.1. Untapped emerging economies
3.6.3.2. Increasing awareness regarding breast cancer

CHAPTER 4 GLOBAL BREAST BIOPSY MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Key market trends
4.1.2. Growth factors and opportunities
4.1.3. Market size and forecast
4.2. VACUUM ASSISTED BIOPSY (VAB)
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. CORE NEEDLE BIOPSY (CNB)
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. FINE NEEDLE ASPIRATION BIOPSY (FNAB)
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 GLOBAL BREAST BIOPSY MARKET, BY IMAGE GUIDED TECHNOLOGY
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. MRI-GUIDED BREAST BIOPSY
5.2.1. Market size and forecast
5.3. ULTRASOUND GUIDED BREAST BIOPSY
5.3.1. Market size and forecast
5.4. MAMMOGRAPHY GUIDED STEREOTACTIC BIOPSY
5.4.1. Market size and forecast
5.5. CT-GUIDED BIOPSY
5.5.1. Market size and forecast
5.6. OTHER IMAGE GUIDED BREAST BIOPSY
5.6.1. Market size and forecast

CHAPTER 6 GLOBAL BREAST BIOPSY MARKET, BY END USER
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. DIAGNOSTIC CENTER
6.2.1. Market size and forecast
6.3. HOSPITAL
6.3.1. Market size and forecast

CHAPTER 7 BREAST BIOPSY MARKET, BY REGION
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Growth factors and opportunities
7.2.3. Market size and forecast by Country
7.2.4. Market size and forecast by Product
7.2.5. Market size and forecast by Image Guided Technology
7.2.6. Market size and forecast by End User
7.2.6.1. U.S. market size and forecast
7.2.6.2. Canada market size and forecast
7.2.6.3. Mexico market size and forecast
7.3. EUROPE
7.3.1. Key market trends
7.3.2. Growth factors and opportunities
7.3.3. Market size and forecast by Country
7.3.4. Market size and forecast by Product
7.3.5. Market size and forecast by Image Guided Technology
7.3.6. Market size and forecast by End User
7.3.6.1. UK market size and forecast
7.3.6.2. France market size and forecast
7.3.6.3. Germany market size and forecast
7.3.6.4. Italy market size and forecast
7.3.6.5. Spain market size and forecast
7.3.6.6. Russia market size and forecast
7.3.6.7. Rest of Europe market size and forecast
7.4. ASIA-PACIFIC
7.4.1. Key market trends
7.4.2. Growth factors and opportunities
7.4.3. Market size and forecast by Country
7.4.4. Market size and forecast by Product
7.4.5. Market size and forecast by Image Guided Technology
7.4.6. Market size and forecast by End User
7.4.6.1. Japan market size and forecast
7.4.6.2. China market size and forecast
7.4.6.3. India market size and forecast
7.4.6.4. Australia market size and forecast
7.4.6.5. Singapore market size and forecast
7.4.6.6. Philippines market size and forecast
7.4.6.7. Rest of Asia-Pacific market size and forecast
7.5. LAMEA
7.5.1. Key market trends
7.5.2. Growth factors and opportunities
7.5.3. Market size and forecast by Country
7.5.4. Market size and forecast by Product
7.5.5. Market size and forecast by Image Guided Technology
7.5.6. Market size and forecast by End User
7.5.6.1. Brazil market size and forecast
7.5.6.2. Turkey market size and forecast
7.5.6.3. Israel market size and forecast
7.5.6.4. Saudi Arabia market size and forecast
7.5.6.5. South Africa market size and forecast
7.5.6.6. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES
8.1. HOLOGIC INC.
8.1.1. Company overview
8.1.2. Operating business segments
8.1.3. Business performance
8.1.4. Key strategic moves and developments
8.2. LEICA BIOSYSTEMS NUSSLOCH GMBH (DEVICOR MEDICAL PRODUCTS, INC.)
8.2.1. Company overview
8.2.2. Operating business segments
8.2.3. Business performance
8.2.4. Key strategic moves and developments
8.3. C. R. BARD, INC.
8.3.1. Company overview
8.3.2. Operating business segments
8.3.3. Business performance
8.3.4. Key strategic moves and developments
8.4. BECTON DICKINSON AND COMPANY
8.4.1. Company overview
8.4.2. Operating business segments
8.4.3. Business performance
8.4.4. Key strategic moves and developments
8.5. ARGON MEDICAL DEVICES
8.5.1. Company overview
8.5.2. Operating business segments
8.5.3. Business performance
8.5.4. Key strategic moves and developments
8.6. COOK MEDICAL INCORPORATED
8.6.1. Company overview
8.6.2. Operating business segments
8.6.3. Business performance
8.6.4. Key strategic moves and developments
8.7. ENCAPSULE MEDICAL DEVICES LLC.
8.7.1. Company overview
8.7.2. Operating business segments
8.7.3. Business performance
8.7.4. Key strategic moves and developments
8.8. ETHICON ENDO SURGERY (JOHNSON & JOHNSON)
8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Business performance
8.8.4. Key strategic moves and developments
8.9. INTACT MEDICAL CORPORATION
8.9.1. Company overview
8.9.2. Operating business segments
8.9.3. Business performance
8.9.4. Key strategic moves and developments
8.10. GALINI SRL
8.10.1. Company overview
8.10.2. Operating business segments
8.10.3. Business performance
8.10.4. Key strategic moves and developments

List of Tables
Table 1. Global Breast Biopsy Market, By Product, 2016-2023 ($Million)
Table 2. Global Vacuum Assisted Biopsy (Vab) Market, By Region, 2016-2023 ($Million)
Table 3. Global Core Needle Biopsy (Cnb) Market, By Region, 2016-2023 ($Million)
Table 4. Global Fine Needle Aspiration Biopsy (Fnab) Market, By Region, 2016-2023 ($Million)
Table 5. Global Breast Biopsy Market, By Image Guided Technology, 2016-2023 ($Million)
Table 6. Global Mri-Guided Breast Biopsy Market, By Region, 2016-2023 ($Million)
Table 7. Global Ultrasound Guided Breast Biopsy Market, By Region, 2016-2023 ($Million)
Table 8. Global Mammography Guided Stereotactic Biopsy Market, By Region, 2016-2023 ($Million)
Table 9. Global Ct-Guided Breast Biopsy Market, By Region, 2016-2023 ($Million)
Table 10. Global Other Image Guided Breast Biopsy Market, By Region, 2016-2023 ($Million)
Table 11. Global Breast Biopsy Market, By End USer, 2016-2023 ($Million)
Table 12. Global Breast Biopsy Market For Diagnostic Center, By Region, 2016-2023 ($Million)
Table 13. Global Breast Biopsy Market For Hospital, By Region, 2016-2023 ($Million)
Table 14. Global Breast Biopsy Market, By Region, 2016-2023 ($Million)
Table 15. North America Breast Biopsy Market, By Country, 2016-2023 ($Million)
Table 16. North America Breast Biopsy Market, By Product, 2016-2023 ($Million)
Table 17. North America Breast Biopsy Market, By Image Guided Technology, 2016-2023 ($Million)
Table 18. North America Breast Biopsy Market, By End USer, 2016-2023 ($Million)
Table 19. Europe Breast Biopsy Market, By Country, 2016-2023 ($Million)
Table 20. Europe Breast Biopsy Market, By Product, 2016-2023 ($Million)
Table 21. Europe Breast Biopsy Market, By Image Guided Technology, 2016-2023 ($Million)
Table 22. Europe Breast Biopsy Market, By End USer, 2016-2023 ($Million)
Table 23. Asia-Pacific Breast Biopsy Market, By Country, 2016-2023 ($Million)
Table 24. Asia-Pacific Breast Biopsy Market, By Product, 2016-2023 ($Million)
Table 25. Asia-Pacific Breast Biopsy Market, By Image Guided Technology, 2016-2023 ($Million)
Table 26. Asia-Pacific Breast Biopsy Market, By End USer, 2016-2023 ($Million)
Table 27. Lamea Breast Biopsy Market, By Country, 2016-2023 ($Million)
Table 28. Lamea Breast Biopsy Market, By Product, 2016-2023 ($Million)
Table 29. Lamea Breast Biopsy Market, By Image Guided Technology, 2016-2023 ($Million)
Table 30. Lamea Breast Biopsy Market, By End USer, 2016-2023 ($Million)
Table 31. Hologic: Company Snapshot
Table 32. Hologic: Operating Segments
Table 33. Leica Biosystems: Company Snapshot
Table 34. Leica Biosystems: Operating Segments
Table 35. C. R. Bard: Company Snapshot
Table 36. C. R. Bard: Operating Segments
Table 37. Becton Dickinson: Company Snapshot
Table 38. Becton Dickinson: Operating Segments
Table 39. Argon: Company Snapshot
Table 40. Argon: Operating Segments
Table 41. Cook Medical: Company Snapshot
Table 42. Cook Medical: Operating Segments
Table 43. Encapsule Medical: Company Snapshot
Table 44. Encapsule Medical: Operating Segments
Table 45. Ethicon: Company Snapshot
Table 46. Ethicon: Operating Segments
Table 47. Intact Medical: Company Snapshot
Table 48. Intact Medical: Operating Segments
Table 49. Galini: Company Snapshot
Table 50. Galini: Operating Segments

List of Figures
Figure 1. Global Breast Biopsy Market, 2016-2023
Figure 2. Segmentation Of Global Breast Biopsy Market
Figure 3. Top Winning Strategies: Percentage Distribution, 2014-2017
Figure 4. Top Winning Strategies: By Nature, & Type Of Development, 2014-2017
Figure 5. Top Investment Pockets
Figure 6. Bargaining Power Of Buyers
Figure 7. Bargaining Power Of Suppliers
Figure 8. Threat Of New Entrants
Figure 9. Threat Of Substitution
Figure 10. Competitive Rivalry
Figure 11. Top Player Positioning: Global Breast Biopsy Market, 2016
Figure 12. U.S. Breast Biopsy Market, 2016-2023 ($Million)
Figure 13. Canada Breast Biopsy Market, 2016-2023 ($Million)
Figure 14. Mexico Breast Biopsy Market, 2016-2023 ($Million)
Figure 15. UK Breast Biopsy Market, 2016-2023 ($Million)
Figure 16. France Breast Biopsy Market, 2016-2023 ($Million)
Figure 17. Germany Breast Biopsy Market, 2016-2023 ($Million)
Figure 18. Italy Breast Biopsy Market, 2016-2023 ($Million)
Figure 19. Spain Breast Biopsy Market, 2016-2023 ($Million)
Figure 20. Russia Breast Biopsy Market, 2016-2023 ($Million)
Figure 21. Rest Of Europe Breast Biopsy Market, 2016-2023 ($Million)
Figure 22. Japan Breast Biopsy Market, 2016-2023 ($Million)
Figure 23. China Breast Biopsy Market, 2016-2023 ($Million)
Figure 24. India Breast Biopsy Market, 2016-2023 ($Million)
Figure 25. Australia Breast Biopsy Market, 2016-2023 ($Million)
Figure 26. Singapore Breast Biopsy Market, 2016-2023 ($Million)
Figure 27. Philippines Breast Biopsy Market, 2016-2023 ($Million)
Figure 28. Rest Of Asia-Pacific Breast Biopsy Market, 2016-2023 ($Million)
Figure 29. Brazil Breast Biopsy Market, 2016-2023 ($Million)
Figure 30. Turkey Breast Biopsy Market, 2016-2023 ($Million)
Figure 31. Israel Breast Biopsy Market, 2016-2023 ($Million)
Figure 32. Saudi Arabia Breast Biopsy Market, 2016-2023 ($Million)
Figure 33. South Africa Breast Biopsy Market, 2016-2023 ($Million)
Figure 34. Rest Of Lamea Breast Biopsy Market, 2016-2023 ($Million)
Figure 35. Hologic: Revenue, 2014-2016 ($Million)
Figure 36. Hologic: Revenue By Segment, 2016 (%)
Figure 37. Hologic: Revenue By Geography, 2016 (%)
Figure 38. Leica Biosystems: Revenue, 2014-2016 ($Million)
Figure 39. Leica Biosystems: Revenue By Segment, 2016 (%)
Figure 40. Leica Biosystems: Revenue By Geography, 2016 (%)
Figure 41. C. R. Bard: Revenue, 2014-2016 ($Million)
Figure 42. C. R. Bard: Revenue By Segment, 2016 (%)
Figure 43. C. R. Bard: Revenue By Geography, 2016 (%)
Figure 44. Becton Dickinson: Revenue, 2014-2016 ($Million)
Figure 45. Becton Dickinson: Revenue By Segment, 2016 (%)
Figure 46. Becton Dickinson: Revenue By Geography, 2016 (%)
Figure 47. Argon: Revenue, 2014-2016 ($Million)
Figure 48. Argon: Revenue By Segment, 2016 (%)
Figure 49. Argon: Revenue By Geography, 2016 (%)
Figure 50. Cook Medical: Revenue, 2014-2016 ($Million)
Figure 51. Cook Medical: Revenue By Segment, 2016 (%)
Figure 52. Cook Medical: Revenue By Geography, 2016 (%)
Figure 53. Encapsule Medical: Revenue, 2014-2016 ($Million)
Figure 54. Encapsule Medical: Revenue By Segment, 2016 (%)
Figure 55. Encapsule Medical: Revenue By Geography, 2016 (%)
Figure 56. Ethicon: Revenue, 2014-2016 ($Million)
Figure 57. Ethicon: Revenue By Segment, 2016 (%)
Figure 58. Ethicon: Revenue By Geography, 2016 (%)
Figure 59. Intact Medical: Revenue, 2014-2016 ($Million)
Figure 60. Intact Medical: Revenue By Segment, 2016 (%)
Figure 61. Intact Medical: Revenue By Geography, 2016 (%)
Figure 62. Galini: Revenue, 2014-2016 ($Million)
Figure 63. Galini: Revenue By Segment, 2016 (%)
Figure 64. Galini: Revenue By Geography, 2016 (%)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
according to a new report. published by Allied Market Research titled, Breast Biopsy Market by Product and End User - Global Opportunity Analysis and Industry Forecast, 2017-2023, the global breast biopsy market was valued at $977 million in 2016, and is projected to reach at $1,420 million by 2023, growing at a CAGR of 5.3% from 2017 to 2023. Core needle biopsy (CNB) segment accounted for about half of the global market share in 2016.

A breast biopsy is the procedure of locating a diseased tissue in the breast and collecting the specimen sample of the area for further examination and diagnosis. Breast biopsies are performed by using minimally invasive biopsy systems, owing to minimal disfigurement and pain. Non-invasive biopsy techniques provide preventive measures that assist physicians in diagnosing and treating high-risk breast cancer. This information prevents the application of chemotherapy in breast cancer, reducing the complexities of chemo-radiations. Vacuum assisted breast biopsy devices (VAB), core needle biopsies and fine needle aspiration biopsy are commonly used to perform biopsy procedures.

The major factors that boost the market growth include rise in incidence of breast cancer, growth in awareness toward cancer screening programs, and increase in demand for minimal invasive breast biopsies. Moreover, the ongoing technological advancements of diagnostic and treatment technology for breast cancer have undergone a gradual transition from open surgery to minimal invasive biopsy procedures. Breast cancer is the most common type of cancer in women, especially in the U.S., where it is the second leading cause of death propels the demand for breast biopsy procedures. Furthermore, requirement of robust measures for disease control, the thrust for newer technologies has led to the development of minimal invasive surgeries. This has made breast biopsy as preferred modality to diagnose breast cancer and identify complex tumors and make accurate diagnosis. However, lack of awareness toward the availability of novel breast biopsy techniques and risk of infection involved in the procedures are projected to hamper the market growth.

The core needle biopsy (CNB) segment dominated the global market in 2016, and is expected to maintain this trend throughout the analysis period, owing to the less invasive procedure compared to others and it provides more definitive diagnosis. Moreover, use of CNB and ultrasonographic and mammographic guidance is highly accurate for diagnosing breast cancer that supplements the market growth.

The ultrasound guided biopsy is poised to grow at the highest rate during the forecast period, owing to the sound waves used instead ionizing radiation to locate abnormality or lump and is less invasive in nature with reduced scars. Ultrasound guided biopsy segment is expected to grow at a high CAGR of 6.1% from 2017 to 2023.

Asia-Pacific is anticipated to grow at a highest rate throughout the analysis period, owing to the continuous growth in countries, such as Japan, India, China, and Australia. For instance, in Japanese women between the age group of 30-64, breast cancer is one of the leading cancer types over the past decade. In addition, as per Japanese Society of Breast Health, one in every 20 women are diagnosed with breast cancer in Japan. This is a clear trend toward the increase in demand for breast biopsy procedures for screening and diagnosis of breast cancer at early stages. Furthermore, commandment by the government bodies for routine screening for breast cancer after the age of 40 for women has raised the demand for breast biopsy devices. Technological advancements for cost-effective devices in these nations offer a lucrative opportunity for the breast biopsy market growth.

Key Findings of the Breast Biopsy Market:

In 2016, core needle biopsy (CNB) led the overall breast biopsy market revenue, and is projected to grow at a CAGR of 5.6% during the forecast period.
The mammography guided stereotactic biopsy segment occupied the highest share among image guided technology in 2016, and is expected to grow at a CAGR of 5.6%.
In 2016, North America generated highest revenue, region-wise, with over three-sevenths share of the global market.
The number of breast biopsy procedures is growing at a CAGR of 4.2% from 2017 to 2023.
The ultrasound guided biopsy segment is expected to witness the highest growth rate from 2017 to 2023.

Key players operating in the market include Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll